1. A pharmaceutical composition characterized in that it comprises an activated-potentiated form of antibodies to gamma-interferon and human activated-potentiated form of antibodies to brain-specific protein S-100.2. A pharmaceutical composition according to claim 1, characterized in that it comprises an activated-potentiated form of antibodies to gamma-interferon and human activated-potentiated form of antibodies to S-100 brain-specific proteins are used to treat diffuse skleroza.3. A pharmaceutical composition according to claim 1 or 2, characterized in that the activated-potentiated form of antibodies to gamma-interferon and human activated-potentiated form of antibodies to brain-specific protein S-100 is used in the activated potentiated form aqueous or aqueous-alcohol solution obtained in the process multiple serial dilutions of the respective matrix solution of antibodies in an aqueous or aqueous-alcoholic solvent, and an intermediate external mechanical impact - shaking kazh th razvedeniya.4. A pharmaceutical composition according to claim 3, characterized in that it is formed in a solid dosage form and comprises an effective amount of saturated activated-potentiated form of antibodies to gamma-interferon and human antibodies to brain-specific protein S-100 neutral carrier granules and pharmaceutically acceptable dobavki.5. A pharmaceutical composition according to claim 3, characterized in that the aqueous or aqueous-alcoholic solutions of the activated-potentiated forms of antibodies to gamma-interferon and human brain-specific protein S-100 produced by many1. Фармацевтическая композиция, характеризующаяся тем, что содержит активированную-потенцированную форму антител к гамма-интерферону человека и активированную-потенцированную форму антител к мозгоспецифическому белку S-100.2. Фармацевтическая композиция по п.1, характеризующаяся тем, что содержит активированную-потенцированную форму антител к гамма-интерферону человека и активированную-потенцированную фо
